TrialProstate cancer and prostatic diseases2022

LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.

Carsten-Henning Ohlmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.